Biodexa Pharmaceuticals PLC Biodexa Announces Allowance of U.S. Patent Covering Tolimidone Biodexa plans to initiate a Phase 2 clinical program of tolimidone in Type 1 diabetes, following several preclinical studies demonstrating its role in beta cell survival Safety profile established in prior human studies of more than 700 patients CARDIFF, United Kingdom, February 7, 2024 (GLOBE NEWSWIRE) -- Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company")(NASDAQ:BDRX), a clinical stage biopharmaceutical company ...

Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024 CARDIFF, United Kingdom, Jan. 22, 2024 (GLOBE NEWSWIRE) – Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs including Type 1 diabetes and rare / orphan brain cancers, today announced that Stephen Stamp, CEO and CFO of Bi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _______________ OR ☐ SHELL COMPANY PURSUANT T ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _______________ OR ☐ SHELL COMPANY PURSUANT T ...

Midatech Pharma plc (MTP) Q2 2021 Earnings Conference Call September 20, 2021 12:30 PM ET Company Participants Tim Metcalfe - MD, IFC Advisory Limited, IR Stephen Stamp - CEO & CFO Conference Call Participants Tim Metcalfe Well, it seems like most people are with us now. So welcome, my name is Tim Metcalfe. And with me today, I've got Stephen Stamp, who's CEO and CFO of Midatech Pharma. Unfortunately, Stephen is traveling on business at the moment, and where he is, the internet connection is not great. So u ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _______________ OR o SHELL COMPANY PURSUANT T ...

Interims 2020 10 September 2020 The Midatech senior team | --- | --- | --- | --- | |-------|-------|-------|--------------------------------------------| | | | | LEFT TO RIGHT | | | | | Fiona Sharp | | | | | Group Controller | | | | | Sam Barker | | | | | Director Business Development | | | | | Stephen Stamp | | | | | CEO and CFO | | | | | Paul Seaman | | | | | VP Pharmaceutical & Technology Development | | | | | Steve Damment | | | | | EVP R&D | 2 Disclaimer The following presentation, including a hard cop ...

Financial Data and Key Metrics Changes - The first half of 2020 saw a significant non-cash impairment charge of £11.59 million due to the cessation of the MTD201 program [29] - The operating loss for the first half was similar to the previous year, with expectations for a lower loss in the second half due to the closure of operations in Spain [31] - At the half-year mark, the company had net cash of £3.59 million, with a pro forma net cash position of £9.7 million after recent fundraising efforts [32] Business Line Data and Key Metrics Changes - The company has shifted its focus from MTD201 to a diversified pipeline with nine molecules covering 11 indications, enhancing risk allocation [17][18] - The Q-Sphera technology is now the core of the company's strategy, with two collaborations signed in a short timeframe, indicating a more balanced approach to internal and external programs [14][16] Market Data and Key Metrics Changes - The strategic review was initiated due to the collapse in capital markets and the withdrawal of a prospective licensee, impacting the company's operational strategy [5][6] - The company is exploring expressions of interest in individual assets while terminating the formal sale process due to a lack of credible offers [10] Company Strategy and Development Direction - The realigned strategy focuses on licensing Q-Sphera products to pharmaceutical companies for multimillion-dollar milestones and royalties, reducing cash requirements and resource intensity [11][16] - The company will no longer undertake human clinical studies unless fully funded by collaborators, allowing for more simultaneous projects [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's financial position and the traction gained from the Q-Sphera strategy, projecting a cash runway into the fourth quarter of 2021 [33] - The company is cautiously optimistic about the future, with plans to approach regulators for potential early approval of MTX110 if Phase II studies yield positive results [27] Other Important Information - The company is negotiating with contract manufacturing organizations (CMOs) to continue the production of Q-Sphera products following the closure of its Bilbao facility [43][44] - The company intends to maintain both its AIM and Nasdaq listings [45] Q&A Session Summary Question: What are the expected timelines for collaborations to convert to formal development partnerships? - Management indicated that the partner controls the timetable, with a target to land the first license fee in the first quarter of the following year [35] Question: Is there an update on the situation with Secura Bio? - The company is considering a negotiated settlement rather than a costly court process, as the license agreement is not favorable [37][38] Question: Will MTD201 be considered for sale if the right offer arises? - Management confirmed that MTD201 could be sold if a suitable offer is made, as it has provided valuable proof of concept for Q-Sphera technology [39][40] Question: Is the current strategy the long-term direction for the company? - Management affirmed that the current strategy is indeed the long-term plan, focusing on early partnerships rather than costly clinical trials [41][42] Question: How will the company manufacture Q-Sphera products going forward? - The company is in discussions with CMOs to utilize salvaged equipment from Bilbao for clinical trial scale manufacturing [43][44] Question: What is the status of the EU SME status application? - Management expressed frustration over the delay in response from the EU regarding SME status, which affects funding opportunities [48][49][50] Question: Has there been an independent assessment of the company's value post-strategic review? - Management mentioned that brokers have provided valuation models, estimating the company's value at approximately £65 million [51][52]

Financing and Capital Raising - The Group raised gross proceeds of £13.4 million in February 2019 and £2.4 million in October 2019 through various offerings [771]. - A registered direct offering in May 2020 raised $3.0 million and £1.8 million in the UK, indicating ongoing capital-raising efforts [771]. - The Group anticipates requiring additional financing within the next 12 months to support development programs and operations, raising substantial doubt about its ability to continue as a going concern [771]. - The Group is evaluating near-term funding options, including fundraising and asset partnerships, as part of its strategic review [773]. - The Group's ability to continue as a going concern depends on obtaining additional capital or disposing of assets, with no assurance of timely or favorable terms [774]. Operational Risks - The impact of COVID-19 has introduced increased uncertainty over forecasts, potentially causing delays in operations [772]. - Liquidity risk arises from working capital management, with the aim to settle financial obligations as they become due [770]. Financial Risks - The total exposure to credit risk is equal to the total value of financial assets held at year-end, with a loss allowance recognized for expected credit losses [765]. - Foreign exchange risk is significant due to operations in Spain, with currency fluctuations impacting net assets when translated into British pounds sterling [768]. - The Group does not hedge its net investments in overseas operations due to the disproportionate cost relative to exposure [768].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _______________ OR ☐ SHELL COMPANY PURSUANT T ...